Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Quality of life with defibrillator therapy or amiodarone in heart failure.

Mark DB, Anstrom KJ, Sun JL, Clapp-Channing NE, Tsiatis AA, Davidson-Ray L, Lee KL, Bardy GH; Sudden Cardiac Death in Heart Failure Trial Investigators..

N Engl J Med. 2008 Sep 4;359(10):999-1008. doi: 10.1056/NEJMoa0706719.

2.

Effect of PCI on quality of life in patients with stable coronary disease.

Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz C, Zhang W, Hartigan PM, Lewis C, Veledar E, Bowen J, Dunbar SB, Deaton C, Kaufman S, O'Rourke RA, Goeree R, Barnett PG, Teo KK, Boden WE; COURAGE Trial Research Group., Mancini GB.

N Engl J Med. 2008 Aug 14;359(7):677-87. doi: 10.1056/NEJMoa072771.

3.

Coronary intervention for persistent occlusion after myocardial infarction.

Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, Forman S, Ruzyllo W, Maggioni AP, White H, Sadowski Z, Carvalho AC, Rankin JM, Renkin JP, Steg PG, Mascette AM, Sopko G, Pfisterer ME, Leor J, Fridrich V, Mark DB, Knatterud GL; Occluded Artery Trial Investigators..

N Engl J Med. 2006 Dec 7;355(23):2395-407.

4.

Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).

Mark DB, Nelson CL, Anstrom KJ, Al-Khatib SM, Tsiatis AA, Cowper PA, Clapp-Channing NE, Davidson-Ray L, Poole JE, Johnson G, Anderson J, Lee KL, Bardy GH; SCD-HeFT Investigators..

Circulation. 2006 Jul 11;114(2):135-42.

5.

Design and methodology of the Occluded Artery Trial (OAT).

Hochman JS, Lamas GA, Knatterud GL, Buller CE, Dzavik V, Mark DB, Reynolds HR, White HD; Occluded Artery Trial Research Group..

Am Heart J. 2005 Oct;150(4):627-42.

PMID:
16209957
6.
7.

Medical economics and the assessment of value in cardiovascular medicine: Part I.

Mark DB, Hlatky MA.

Circulation. 2002 Jul 23;106(4):516-20. No abstract available.

9.

Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes.

Mark DB, Harrington RA, Lincoff AM, Califf RM, Nelson CL, Tsiatis AA, Buell H, Mahaffey KW, Davidson-Ray L, Topol EJ.

Circulation. 2000 Feb 1;101(4):366-71.

10.

Measurement of health state utilities for economic appraisal.

Torrance GW.

J Health Econ. 1986 Mar;5(1):1-30. Review.

PMID:
10311607
11.

Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators.

Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks MM, Pitt B, Reeder G, Ryan T, Smith H, Whitlow P, Wiens R, Mark DB.

N Engl J Med. 1997 Jan 9;336(2):92-9.

12.

Initial functional and economic status of patients with multivessel coronary artery disease randomized in the Bypass Angioplasty Revascularization Investigation (BARI).

Hlatky MA, Charles ED, Nobrega F, Gelman K, Johnstone I, Melvin J, Ryan T, Wiens R, Pitt B, Reeder G, et al.

Am J Cardiol. 1995 Mar 23;75(9):34C-41C.

PMID:
7892821
13.

A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index).

Hlatky MA, Boineau RE, Higginbotham MB, Lee KL, Mark DB, Califf RM, Cobb FR, Pryor DB.

Am J Cardiol. 1989 Sep 15;64(10):651-4.

PMID:
2782256
Items per page

Supplemental Content

Support Center